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The initial diagnosis of Diabetic Retinopathy (DR) is often in the advance stages of the 
condition, as patients are only promoted for an examination when sight has been affected.  
An innovative prognostic technique has recently been made available which can non-
invasively detect the damaging effects of high blood glucose before the development of 
clinical symptoms.  This innovation offers the opportunity to patients to make the 
necessary behavioural and medicinal modification to prevent further progress of the 
disease.  This paper reports the development of a Markov model which emulates the 
natural progression of Diabetic Retinopathy based on data from clinical trials.  The 
purpose of such a model is to estimate the chronic cost and health outcomes of DR, and it 
may be modified to reflect the potential changes in current practice or condition changes, 
hence allowing for an economic evaluation of the DR prognostic test.  The implications 
and limitations of the model were also discussed in the paper. 
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Introduction 
Diabetic Retinopathy (DR) is a debilitating complication of diabetes, where the 
micro-vascular network of the retina becomes damaged, unable to control blood flow, 
and, as the condition worsens, start to proliferate.  It is also one of the leading causes 
of blindness in the western world both for people of working age and those aged over 
65 (Bamashmus, Matlhaga et al. 2004).   
There is evidence that both Diabetes Mellitus (DM) and DR may be prevented or at 
least their progression slowed.  Results from the Da Qing Impaired Glucose Tolerance 
(IGT) study (Pan, Li et al. 1997), the Malmo Feasibility Study (Eriksson and 
Lindgarde 1991) and the Finnish Diabetes Prevention Study (Tuomilehto, Lindstrom 
et al. 2001), indicate that progression from pre-DM, a condition of impaired fasting 
glucose and or impaired glucose tolerance, to DM may be slowed by weight 
reduction, sufficient exercise and/or appropriate diet.  The UKPDS (UK Prospective 
Diabetes Study Group 1998; Kohner, Stratton et al. 2001; Stratton, Kohner et al. 
2001) and WESDR (Batchelder and Barricks 1995) studies also provide evidence that 
strict control of blood glucose, blood pressure and weight can slow the progression of 
DR. 
Currently, a diagnosis of DR is undertaken using dilated fundus microscopies 
performed by optometrists or ophthalmologists.  However, DR and DM are often not 
diagnosed until the disease is advanced when sight is likely to have already been 
affected.  Although laser treatment may be used to slow the progression to blindness 
in these advanced stages, these treatments also permanently damage the retina.  Thus 
it seems logical that preventing the development of DR or identifying it early will 
increase the likelihood that an individual will retain sight, maintain a good quality of 
life and avoid the discomfort and cost of treatment  (Javitt, Aiello et al. 1994). 
Our laboratory has developed a novel, non-invasive prognostic device aimed at 
identifying the earliest stages of DR (Martin and Markhotina 2003). This innovation 
(prog-DR) can detect the damaging effects of high blood glucose on the retinal 
microvasculature, before the development of clinical symptoms.  It is expected that 
this test will be able to identify pre-diabetics as well as undiagnosed diabetics who 
have not developed DR. 
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Despite the intrinsic appeal of this technology, it is important to systematically assess 
the associated outcomes and costs. Although a randomised controlled trial, including 
an economic evaluation would be the most powerful means of determining the value 
of the test, such trials require large amounts of time and infrastructure and are 
expensive. To circumvent these limitations and to study the feasibility of the test 
before committing to a randomised clinical trial, models are often used to simulate 
real-world conditions, to forecast future outcomes, as well as predict outcomes when 
conditions such as prevalence rates, compliance to medications, costs are so on are 
variable, especially in chronic diseases such as diabetes (Eastman, Javitt et al. 1997; 
Lamotte, Annemans et al. 2002; The CDC Diabetes Cost-effectiveness Group 2002; 
Clarke, Gray et al. 2004; Zhou, Isaman et al. 2005).  Although there are various 
models of interventions for DM (Eastman, Javitt et al. 1997; Lamotte, Annemans et 
al. 2002; The CDC Diabetes Cost-effectiveness Group 2002; Clarke, Gray et al. 2004; 
Zhou, Isaman et al. 2005) and or DR(Dasbach, Fryback et al. 1991; Vijan, Hofer et al. 
2000; Sharma, Hollands et al. 2001; Davies, Roderick et al. 2002; Harper, Sayyad et 
al. 2003), these often fail to include patient behaviour such as diet, exercise patterns 
and response to treatment and screening recommendations (i.e. compliance) nor do 
they include pre-DM as a state in the model.  
Economic evaluations are used to assess the costs and consequences of alternative 
interventions, in this case, comparing a prognostic test for DR with no test. Such 
evaluations fall into four categories: cost minimisation, cost utility, cost benefit or 
cost effectiveness analyses.  The aim of this paper is to describe the development of a 
Markov model designed to estimate the costs and consequences of pre-DR screening.  
Methods 
The Markov model was built in Microsoft Excel 2003 Professional edition on an IBM 
Intel Celeron computer. Markov
 models are used to describe random processes that 
evolve over time. The most common application of Markov models in health is to
 
characterize all the possible prognoses for a given group
  of patients. This entails 
modeling the progress over time of
  a notional group of patients through a finite 
number of health
 states. Patients are initially placed into one of the health states,
 and 
the probabilities of transition to the other states in the model
 are defined within a 
given time period, known as a Markov cycle.
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Markov Progression Model 
The natural progression of DR is shown in Figure 1. The ideal scenario would be to 
prevent DM and DR, which would involve diagnosis at the pre-DM and pre-DR stage, 
before the development of symptomatic damage to sight associated with DM and/or 
DR.  The aim of early diagnosis is to enable patients to modify their lifestyle and/or 
undergo medical interventions earlier, thus increasing the probability of preventing or 
slowing the progression to DM and DR.  Although there  have been reports of cases 
of regression of DR as a result of interventions, the reported incidence is 
low(Kawasaki, Hasegawa et al. 2006); hence the model assumes a uni-directional 
flow of progression, and the transition of the disease is only to more advanced stages.  
However, subjects may skip one or more stages and move into more advanced stages. 
Although this pre-symptomatic screening test can also identify non-diagnosed DM 
and hence may have implications for the development of other complications of 
diabetes such as renal failure and cardiovascular disease (CVD), these were not 
included in the model.  This is because the primary aim of the screening test is the 
prevention of DR. There is a positive association between the severity of DR and 
other co-morbidities  of diabetes such as cardiovascular disease (Klein, Klein et al. 
1999; van Hecke, Dekker et al. 2005) ; however, these associations are not always 
straightforward. For example, the probability of individuals with diabetes developing 
cardiovascular disease is better explained by the presence of factors such as 
hypertension (van Hecke, Dekker et al. 2005), and nephropathy (Torffvit, Lovestam-
Adrian et al. 2005) whereas the severity of retinopathy has been shown to be 
associated with a decreased probability of developing CVD(Lovestam-Adrian, 
Hansson-Lundblad et al. in press). Diabetic nephropathy, which is also a micro-
vascular complication of diabetes, shows more consistent association with the severity 
of DR (Villar, Garcia et al. 1999; Rossing, Hougaard et al. 2002) however, glycemic 
(Powrie, Watts et al. 1994; Villar, Garcia et al. 1999) and blood pressure control 
(Stephenson, Fuller et al. 1995; Schrier, Estacio et al. 2002) are still important 
predictors (in conjunction with the presence of retinopathy) of nephropathy. 
As a Markov model uses transition probabilities and most clinical studies present the 
data as hazard rates of progression, these were converted to transitional probabilities  
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The Hypothetical Population 
As the diagnostic test is intended to be performed by optometrists or 
ophthalmologists, the cohort of interest was created by using the number of people 
who attended an optometrist or ophthalmologist for a comprehensive or brief initial 
consultation (Medicare Benefit Schedule (MBS) codes 10900 or 10916 respectively) 
in 2005 (3,017,424 people) (Medicare Australia 2005). The cohort was divided into 
two groups based on eligibility for the pre-DR test. 
To be eligible, an individual must not have already been diagnosed with DM or DR.  
Undiagnosed diabetics with DR can be identified by dilated fundus microscopy, a 
procedure recommended by the Optometrists Association Australia (OAA) 
(Optometrists Association Australia 2005) for those suspected of DR or DM. The 
OAA also recommends that those with DR are referred to general practitioners for 
further investigation. Therefore, those eligible for the pre-DR test include normal 
subjects, undiagnosed diabetics without DR and pre-diabetics. The latter two groups 
progress through the model. 
Using Australian epidemiological data, the percentage of the hypothetical population 
who are eligible and progress through the model are shown in Table 1 and 2.   
Pre-diabetic progressions and lifestyle characteristics 
Studies have found that pre-diabetics have a very high probability of developing DM. 
The Da Qing IGT study (1997) as well as other clinical studies have shown that 
increases in weight or Body Mass Index (BMI) accelerate the progression to diabetes, 
whilst adhering to a healthy diet and undertaking regular exercise can slow the 
progression (Edelstein, Knowler et al. 1997; Tuomilehto, Lindstrom et al. 2001).   
This model takes into account some of these real-life decisions or characteristics of 
pre-diabetics; one such decision is their choice of diet and exercise patterns which are 
assumed to be related to their body mass index (BMI). According to the Diabesity 
Study, 59.6% of the diabetic population in Australia is overweight (BMI above 25); 
therefore 40.4% can be considered lean.   
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It was assumed that lean subjects have similar diet and exercise patterns to 
respondents to the 2003 NSW Health Survey, where sufficient exercise for a non- 
over weight person was defined as 2.5 hours of physical activity per week and a 
“healthy” diet was defined as one which includes sufficient consumption of fibre 
(Centre for Epidemiology and Research and NSW Department of Health 2004).  For 
overweight subjects, it was assumed that four hours of physical activity per week is 
sufficient, and an appropriate diet include a reduced intake of fat, saturated fat and an 
increased intake of fibre(2001).  However, as subjects are currently not diagnosed 
with pre-DM, it is assumed that they will undertake a pattern of “healthy” diet and 
exercise at the same rate as lean subjects because they do not receive any information 
which would predispose them to attempt a more challenging diet and exercise pattern.  
Based on these data, the lifestyle characteristics of the cohort were estimated and are 
summarized in Table 3. 
The transitional probabilities to DM are based on the Da Qing IGT study (1997) (Pan, 
Li et al. 1997); the probabilities are dependent on the BMI and lifestyle characteristics 
of individuals, so that for the same lifestyle characteristic, lean subjects have a 
reduced probability of progression.  For example, lean subjects with an appropriate 
diet, sufficient exercise or both, have progression probabilities of 0.0770, 0.0496 and 
0.0688, whereas the progression probabilities for overweight subjects are 0.1033, 
0.1127 and 0.1167. 
Diabetic progressions and lifestyle characteristics 
For diabetics, the progression to more severe stages is dependent on two factors.  The 
first is the choice of blood glucose control method, which is usually based on the 
severity of abnormal blood glucose levels.  According to the DiabCo$t study 
(Colagiuri, Colagiuri et al. 2003) 1% of diabetics do not actively attempt to control 
their blood glucose;
  32.7% control their glucose levels through diet and exercise, 
59.6% use hypoglycemic tablets and 6.7% use insulin alone or in combination with 
other hypoglycemic medications.    
The second factor influencing progression is compliance with the chosen blood 
glucose control method; it is assumed that those who comply achieve strict control of 
blood glucose levels, whereas those who do not comply achieve conventional control.  
According to a study by Rubin(Rubin 2005) compliance is lowest for behavioral types 
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of control (diet and exercise) at 5.7%, highest for simple tablet consumption at 61-
85%
 and moderate for insulin injections  (62-64%). 
Individuals who are either a non-diagnosed pre-diabetic or non-diagnosed diabetic do 
not have the information which would enable them to manage their blood glucose 
levels. The model assumes that their management regime consists of diet and 
exercise.  However, under the current screening protocol, around 10.58% of non-
diagnosed diabetics will be identified each year(Dunstan, Zimmet et al. 2001). This 
information is incorporated into the model. 
Non-sight threatening DR (nSTDR) 
The transitional probabilities for the stages of DR - defined as microaneurysm (MA), 
mild non-proliferative DR (nPDR) and moderate nPDR - were derived from the 
UKPDS (UK Prospective Diabetes Study Group 1998).  Despite the availability of 
many other excellent studies on DR progression, the UKPDS was chosen as it was 
based on the more common type of DM (Type 2), involved a large number of 
participants (over 3800) and was conducted over a long period of time (up to 10yrs). 
The UKPDS showed that progression from the early stages of DR was influenced by 
the level of blood glucose control achieved.  That is, a strict blood glucose control 
regime (aimed at achieving an FPG of less than 6 mmol/L), slowed the rate of 
progression compared with conventional blood glucose control methods.  These rates 
of progression were converted to annual transition probabilities and distributed among 
the stages of diabetic retinopathy.  The distribution was based on the assumption that 
progression to the next stage of severity is twice that to the stage after and so on.  The 
transition probabilities are summarized in Table 4.  
For progression to macular oedema, the transition probabilities were based on the 
WESDR (Klein, Klein et al. 1995) as the UKPDS does not include these data.  The 
WESDR cohort was similar to the conventional control group in the UKPDS, as the 
majority of the cohort had a glycosylated hemoglobin (HbA) percentage above 7%.  
As the incidence of macular oedema (maculopathy) was 6.7 times more frequent for 
those with higher (HbA) (Klein, Klein et al. 1995), the transitional probabilities for 
the intensive blood glucose control were divided by this amount. 
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Sight-threatening DR (STDR) 
As DR progresses, more of the retina becomes damaged and the risk of sight being 
affected increases.  The stages at which sight is most likely to be threatened include 
severe nPDR, PDR and macular edema.  The transitional probabilities for severe 
nPDR and PDR were derived from the UKPDS (UK Prospective Diabetes Study 
Group 1998), and the progression to macular oedema was based on the WESDR. A 
summary of the transitional probabilities is shown in Table 4. 
For these sight threatening stages, the progression to more advanced stages is 
influenced by more than the control of blood glucose.  It may also be affected by the 
need for laser treatment and compliance with monitoring and treatment 
recommendations.   
Panretinal and focal laser photocoagulation can be used to restore some eyesight and 
slow the deterioration of the retina. As the laser treatment also causes irreversible 
damage to the retina, due to laser burns, the procedure is not always recommended.  
Identification of the need for treatment is facilitated by compliance with the 
recommendations for monitoring compiled by the National Health and Medical 
Research Council (NHMRC) (National Health and Medical Research Council 1997).   
For example, if the need for laser treatment was not identified (eg if diabetes was not 
diagnosed) or the intervention not carried out, the transitional probability of remaining 
in the current stage (no progression) is reduced to zero and the probability of 
transition to more advanced stages is increased; conversely, identified need and a high 
level of compliance with the intervention would result in a zero rate of deterioration 
and/or probability of progression (if the treatment was successful). 
The probability that laser treatment is needed was based on the UKPDS (UK 
Prospective Diabetes Study Group 1998) which showed the number of people who 
received laser treatment.  It is likely that a person will have both eyes treated.   
Australian hospital data (Yi, Bamroongsuk et al. 2003) was used to estimate the 
average number of eyes treated per patient, which was found to be 1.586 eyes per 
patient. The adjusted annual probability for treatment was then distributed across 
different stages of STDR based on the utilization proportion for each stage (Kohner, 
Stratton et al. 2001).  The annual probabilities for laser treatment for intensive control 
are 0.0001, 0.0025 and 0.0172 for severe nPDR, PDR and ME; and 0.0002, 0.0034 
and 0.0232 for conventional control respectively. 
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The likelihood of individuals complying with these recommendations was based on 
the study by Schoenfeld, Greene, Wu, et al., (2001), which showed that 64.8% of the 
diabetic population fully complied with the diabetes vision care guidelines for eye 
examinations (Aiello, Gardner et al. 2000); 11.1% per cent attended examinations but 
did not undertake all recommended tests (partial compliance), and the remaining 
24.1% did not attend an eye examination at all (zero compliance). 
The probability of treatment is zero for individuals who do not comply with the 
NHMRC recommendations for eye examinations- such an individual would not be 
identified as needing treatment in the first place.  Conversely, the probability of 
treatment is one for those who fully complied with the recommendations.  As the 
NHMRC (National Health and Medical Research Council 1997) recommends three to 
twelve eye examinations per year for maculopathy and four to six eye examinations 
per year for severe nDR and PDR,  it is assumed that a minimum of three or four 
examinations per year is sufficient to decide whether laser treatment is required. As 
partial compliance means that individuals have at least one examination per year, it is 
estimated that there is at least a one in four chance (or one in three for maculopathy) 
that the need for laser treatment will be identified and the same chance that an 
individual will comply with treatment recommendations. The effects of additional eye 
examinations were tested in the sensitivity analysis. 
The success rate for laser treatments was derived from Australian hospital 
data(Bamroongsuk, Yi et al. 2002), based on the assumption that the laser treatment 
was deemed successful if no further treatment was required.  It should be noted 
however that further treatment may not be required or provided due to other reasons 
such as no observed improvement with the treatment regime or non-compliance of 
patients.  As no data about these possibilities were available, the sensitivity of the 
incremental cost-effectiveness ratio (ICER) to variations of the success rate was 
tested.  In the model, base-case success rates for laser treatments are set at 64.9% for 
severe nPDR and PDR and 48.8% for macular edema. 
Blindness and Death 
The transitional probabilities of progressing to blindness were based on studies by 
Janghorbani, Jones and Allison (2000), Lawson, Hunt and Kohner (1985) and the 
UKPDS (UK Prospective Diabetes Study Group 1998). The UKPDS (UK Prospective 
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Diabetes Study Group 1998) shows that the transitional probability of progressing to 
blindness is 1.16 times higher for those with conventional blood glucose control than 
for those who achieve strict control. As the subjects in the blindness studies are 
similar to the conventional blood glucose control group with blood glucose levels 
above 6 mmol/L and HbA above 7% (Lawson, Hunt et al. 1985; Janghorbani, Jones et 
al. 2000), the transitional probabilities to blindness were divided by 1.16 to yield the 
intensive transition probabilities.  These are summarized in Table 5. 
The transitional probabilities of progressing to death were based on a study by Cusick, 
Meleth, Agron, et al., (2005) for Type  2 diabetics.  As the ratio of deaths due to 
diabetes and other causes is 1:1.53 (UK Prospective Diabetes Study Group 1998), the 
transitional probabilities of dying were divided by this ratio to differentiate between 
the two types of mortality. 
In the UKPDS, it was shown that the mortality rate associated with conventional 
blood glucose control is 1.085 time higher than for intensive control (UK Prospective 
Diabetes Study Group 1998).  As the subjects in the study by Cusick, Meleth, Agron, 
et al. (2005) were similar to the conventional blood glucose control group in the 
UKPDS, the transition probabilities were divided by 1.085 to yield the transition 
probabilities for those with intensive blood glucose control.  The transition 
probabilities to death are summarized in Table 6. 
 
It should be noted that it is these transitions probabilities that are likely to ultimately 
affect the outcomes of life years and sight years estimated in the model. 
Health utility measurement (determining QALY scores) 
Quality-adjusted life years (QALYs) and other measures of utility have been 
developed as a means of valuing the trade-off between length of life and health-
related quality of life. A number of approaches such as standard gamble, time trade-
off or rating scales can be used to produce scores which represent the valuation 
attached to a number of health states. The health states cover dimensions such as 
mobility, pain/discomfort, self-care, psychological state and ability to perform usual 
activities. Scores are assigned to different health states so that full health has a score 
of one and death a score of zero.  
9  
In this study, results from a study by Brown, Brown, Sharma, et al., (1999) provided 
utility values for a range of visual acuities associated with DR. A study by Fong, 
Sharza, Chen, et al., (2002) provided information on the range of visual acuity for 
different stages of DR and data from the worst eye was used. The weighted average 
utility scores were derived using a combination of information from these two studies 
and are shown in Table 7. 
Cost data 
Type 2 Diabetes Mellitus is a costly disease. Not only do individuals and society incur 
direct and non-direct health care costs, patients and their carers may also lose income 
and society productivity (Colagiuri, Colagiuri et al. 2003).  In this model, a range of 
health care costs was considered. These were discounted at 3% per annum (Murray 
and Lopez 1996; Mathers, Vos et al. 1999) and varied between 5% and 7% in the 
sensitivity analysis. 
Blood glucose management  
The 2005 Pharmaceutical Benefits Schedule (PBS) (Department of Health and Ageing 
2005) report lists the blood glucose indicators, insulin and other hypoglycemic 
medication available in Australia, including the prices paid by consumers. It is 
assumed that individuals purchase 53 weeks’ worth of medications and medical 
consumables each year (one for each week of the year and one week’s worth of back-
up). The intake of hypoglycemic medications recommended by the Australian 
medicines handbook (AMH 2004) was used in the model and it is assumed that blood 
glucose was measured once per day. 
The Australian government collects pharmaceutical usage information via Medicare 
Australia, and this information is available online: 
(http://www.medicareaustralia.gov.au).  The Australian government also funds a 
National Diabetes Services Scheme (NDSS) which subsidizes syringes and insulin 
pens which registered diabetics can access.  Based on these data, the weighted 
average annual cost for insulin alone or in combinations with other hypoglycemic 
medications was estimated to be $5,329.72 – $6,793.82 per year, $81.92 - $169.91 per 
year for hypoglycaemic tablets and $342.40 per year for blood glucose indicators. 
In order to use these pharmaceutical products, prescriptions and re-assessment of 
dosage are needed.  The Medicare Benefit Schedule (MBS) (Department of Health 
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and Ageing 2004), recommends that diabetics visit a general practitioner twice a year; 
it was assumed that one standard (MBS 2620) and one long consultation (MBS 
22622) would be needed (Department of Health and Ageing 2004).  This adds $59 to 
the cost of blood glucose management. 
Eye examinations 
The MBS price for an eye examination is $60.25 (MBS 10914) (Department of Health 
and Ageing 2004), and the frequencies of eye examinations were based on NHMRC 
recommendations for diabetics (National Health and Medical Research Council 
1997). For those with PDR and ME, fluorescein angiography in one or both eyes is 
recommended by the NHMRC.  The costs of retinal photography, multiple exposures 
of 1 or both eyes with intravenous dye injection (MBS code 11215 or 11218) are 
$104.35 and $128.90 respectively (Department of Health and Ageing 2004); the 
weighted average cost per person of $127, based on usage of these services in the year 
beginning June 2004 (published on the Medicare website), was used. 
The likelihood of compliance with the Australian NHMRC recommendations was 
based on the study by Schoenfeld, Greene, Wu, et al., (2001), which shows that 65% 
of the diabetic population fully comply with the diabetes vision care guidelines for 
eye examinations in America (Aiello, Gardner et al. 2000). Eleven per cent attended 
examinations but did not undertake all recommended tests (partial compliance), and 
the remaining 24% did not attend an eye examination at all (zero compliance). 
As the NHMRC recommends one eye examination every two years for nSTDR, and 
the model cycles annually, partial compliance for these stages was taken as being 
equal to full compliance. 
Laser treatment cost  
Retinal photocoagulation or laser treatment for DR (MBS 42809) costs $382.80 per 
session of treatment (Department of Health and Ageing 2004); however, multiple 
sessions and follow-up treatment are often needed.  Based on Australian hospital data 
(Bamroongsuk, Yi et al. 2002), individuals with either severe nPDR or PDR undergo 
panretinal laser treatment; 99.973% require multiple laser sessions and 35% require 
follow up treatment. As the median waiting and follow-up assessment time indicate 
that no more than 5 treatments sessions are possible each year, the proportion of eyes 
which underwent 1 – 5 laser sessions were estimated.  The weighted average cost of 
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laser treatment per eye was also estimated (including the cost for the excess eye 
consultations above the NHMRC recommendations) and multiplied by the average 
number of eyes treated per patient (Yi, Bamroongsuk et al. 2003). This yielded an 
annual cost per patient of $1959.13. 
Similar estimates were made for macular edema, but since both focal and panretinal 
photocoagulations were used, the weighted average of these treatments of $1604.43 
were used in the calculation of the annual cost per patient. 
Non-health cost of blindness 
The direct non-health costs associated with blindness vary between countries as well 
as states within countries, as different infrastructure and support mechanisms are 
available.  Expert opinion from Mr. M. Simpson from the Royal Blind Society (NSW) 
was used to estimate the costs of blindness (see Table 8). 
Sensitivity Analysis 
The influence of 11 parameters on life years, sight years, QALYs gained and the cost 
were evaluated.  Univariate sensitivity analysis was performed by varying the 
parameters upwards and downwards by 10% (Table 9).  An elasticity test (the 
percentage change in outcome divided by the percentage change in parameter) of 0.8 
or more was considered to be elastic.   
Discussion 
The aim of this paper was to describe a model built to estimate the cost and health 
outcomes of screening for DR. Once constructed, such a model can be modified to 
predict and/or take account of changes in costs and health outcomes associated with 
alterations to policies, practices and/or the health profile of the population.  A Markov 
model was built using information from a combination of sources including clinical 
trials and epidemiology data.  This type of model is a cohort or population based 
model; it does not take into consideration individual progression pathways, but rather 
the progression of the cohort. It is relatively simple type of model, but appropriate for 
the modelling problem at hand (Barton, Bryan et al. 2004). 
It is intended that the model will be modified and estimated assuming that the prog-
DR test is used as a standard prognostic procedure, thereby determining the value of 
this test. In reality, the prog-DR test will need to be further assessed to ensure its 
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safety and efficacy. Once this has been established, a randomised clinical trial would 
provide the most accurate estimates of the effectiveness and cost-effectiveness of the 
test. At this stage, these steps are neither possible nor practical; thus a model is useful 
in predicting and forecasting possible costs and consequences. 
Although models have been previously developed to evaluate interventions for 
DM(Eastman, Javitt et al. 1997; The CDC Diabetes Cost-effectiveness Group 2002; 
Clarke, Gray et al. 2004; Zhou, Isaman et al. 2005) and DR (Vijan, Hofer et al. 2000), 
these were not ideal for this situation for various reasons.  Firstly, the DM models 
include the progression of a wide range of complications such as CVD, nephropathy, 
neuropathy and the portion on DR are often simplified to 3-4 stages(Eastman, Javitt et 
al. 1997; The CDC Diabetes Cost-effectiveness Group 2002; Zhou, Isaman et al. 
2005), considered only as a blindness endpoint (Clarke, Gray et al. 2004; Tilden, 
Mariz et al. 2007) or clustered as a microvascular complication (Lamotte, Annemans 
et al. 2002).  Although this is reasonable for a broad view of DM, it is not sufficient 
for an in-depth study on DR progression.  Also, as previously mentioned, DR is not 
the best predictor of the macrovascular and microvascular complications of DM and 
the association of DR with these complications is not always straight forward.  In this 
study, a conservative approach has been taken and the potential beneficial effects of 
early DR and pre-DM diagnosis on these complications were not included in our 
model. 
Several in depth models on DR progression have been published (Dasbach, Fryback 
et al. 1991; Vijan, Hofer et al. 2000; Sharma, Hollands et al. 2001; Davies, Roderick 
et al. 2002; Harper, Sayyad et al. 2003) and these are well equipped to examine the 
effects of early DR diagnosis.  However, the differentiating ability of the intervention 
to be investigated in this study is its usefulness as a prognostic device for DM and 
DR; hence it is essential to also examine the pre-DR and pre-DM stages of DR 
progression. 
Many reports have shown that patient response to and participation in screening and 
treatment regime are of paramount importance for most diabetic interventions 
(Schoenfeld, Greene et al. 2001; Polak, Crijns et al. 2003) as reviewed by 
Lerman(Lerman 2005), yet these are not often addressed in DM and DR intervention 
models.  For example, studies have shown that compliance to behaviour oriented 
glycemic control is much lower than for simple medications (Rubin 2005); only 16% 
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of diabetic patient received the recommended annual screening in two consecutive 
years (Mukamel, Bresnick et al. 1999) and more than one third of patients do not 
follow screening guidelines (Schoenfeld, Greene et al. 2001).  Therefore, patient 
behaviour such as compliance to screening and treatment recommendations and diet 
and exercise pattern during the pre-DM phase were included in this model as it 
seemed likely that this would have major impact on the cost effectiveness of the prog-
DR test. 
Detailed results of the economic evaluation will be described in a separate paper. 
However, in summary, the base case model predicts that a majority of the 599,393 
individuals with undiagnosed diabetes and pre-diabetes who visit optometrists in a 
one year period, would progress to more severe stages of DR as shown in Figure 2 
and that, on average, an individual would lose 0.03 QALYs (the average QALY score 
per person would decrease from 0.840 to 0.810) over a 10 year period. The model also 
predicts that a total cost of over $4,090 million would be incurred by the health and 
welfare systems with the cost of blindness being the most costly component (more 
than $3,296 million) followed by the cost for blood glucose management (more than 
$627 million). 
Limitations of the model
Markov models lack memory such that the transition probability is only dependent on 
the current state and not any previous states.  This may not always be the case in “real 
life” situations; for example a patient who has been compliant with blood glucose 
management over a number of years is more likely to remain compliant, whereas a 
patient who has been erratic or non-compliant is less likely to comply in the new 
cycle.  This issue may have been overcome by introducing new states in the model 
which are dependent on previous actions; however this would complicate the model 
and is not practical as there are not sufficient data on compliance probabilities of DM 
and DR patients, based on previous compliance. 
An inherent weakness of any model is that it assumes ceteris paribus, that is 
everything remains the same, when this is not always the case. For example, some of 
the data used in this model originated in the 1990s, and since then the management of 
DM, DR and blood glucose levels has improved due to better understanding of the 
disease process and development of improved medications.  Patient behaviour, such 
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as compliance to blood glucose management and eye examinations, which is 
important in determining the success of a diagnostic test, may also change over time.  
Therefore, a model is only as good as the assumptions made, and as reliable as the 
data it was built on. 
An assumption which may not be realistic is that success in blood glucose 
management, (and therefore the reduced probability of progression), is dependent on 
the method used and rate of compliance.  It implicitly assumes that patients will use 
the appropriate management method and that compliance automatically translates to 
success. Unfortunately, this is not always the case, as trial and error may be required 
to find the appropriate blood glucose management method or medication for a patient 
and depending on the severity of the disease, some patients may find it more or less 
difficult to successfully manage their blood glucose levels. 
As mentioned, the model combines the results of research undertaken on populations 
living in UK (UK Prospective Diabetes Study Group 1998), China (Pan, Li et al. 
1997)  and US (Klein, Klein et al. 1995)  and include subjects mostly over 30 years of 
age (Klein, Klein et al. 1995) whereas the hypothetical population is Australian and 
includes patients from all ages.  The assumption is that these data are comparable 
whereas they are in fact the best data available. 
The health utility values are also limited to the data available.  The model requires 
utility values specific to different states of DR; however most authors report utility 
values based on visual acuity (Brown, Brown et al. 1999; Sharma, Oliver-Fernandez 
et al. 2003).  Tung et al reported utility values for different stages of DR (Tung, Chen 
et al. 2005), however the sample size is relatively small (373), the response rate is 
only 44% and the sample population had all been diagnosed with DM for over 10 
years ; in contrast, many members of the hypothetical population would be newly 
diagnosed. 
Therefore, the study by Fong Sharza et al. (2002) on the visual acuity of DR patients 
at different stages was used to translate the utility values for different visual acuity 
levels of DR patients in the study by Brown et al 
41.  It should be noted however, that 
the sample population in the Brown et al study had poor visual acuity (20/40 or 
worse) as the authors found that patients with good vision were unwilling to trade-off 
life years for perfect vision, making it difficult to use the time trade-off method to find 
15  
the utility values.  Also, as the authors suggested, patients with poor visual acuity may 
have already adapted to living with this handicap and hence may not consider a fall in 
visual acuity as having a major impact on their quality of life.  Despite these two 
issues, the study by Brown et al provided the best available data showing that loss of 
vision has a detrimental effect on quality of life. 
In summary, this Markov model for DR progression was able to estimate the DR 
states of a hypothetical cohort, including quality adjusted life years and costs, and can 
be used as to predict potential changes to these outcomes if health policies and 
practices are modified.  The model will be used to estimate the cost effectiveness and 
cost utility of the prog-DR screening test. 
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Figure 1: The progression of DR: Pre-DM is pre-diabetes 
 
Pre-DR is pre diabetic retinopathy that is a diabetic stage without DR; MA is 
micro-aneurysm, nPDR is non-proliferative DR; PDR is proliferative DR and 
ME is macular edema.  The severity of the stages increases from left to right. 
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Figure 2: The progression of DR over time 



























Pre-DM is pre-diabetes; DM is Diabetes Mellitus without clinical signs of DR; 
nSTDR is non-sight threatening Diabetic Retinopathy, and STDR is sight 
threatening Diabetic Retinopathy. 
 
Table 1: The percentage of diagnosed and undiagnosed Diabetics 
with and without DR 
 Undiagnosed  Diabetics  Diagnosed  Diabetics 
With DR   = 3.8%
* x 6.2%
†





Without DR   = 3.8% - 0.2356% 
= 3.5644%  
= 3.8 % - 0.8322 
= 2.9688% 
* The prevalence rate of diagnosed and undiagnosed Diabetes were based on the 
Diabesity study (Dunstan, Zimmet et al. 2001).  
† The prevalence rate for diabetic 
retinopathy were based on the study by Tapp, Shaw, Harper, et al (2003) (Tapp, 
Shaw et al. 2003).  Numbers are rounded to four decimal places. 
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Table 2: The number of subjects eligible for the DR prognostic test 
 
Cohort attending an optometrist  3,017,424 
- Normal  2,296,260 
- DM 
* 114,662 
- Undiagnosed DM with DR 
† 7,109 




* the prevalence of diabetes (Dunstan, Zimmet et al. 2001); 
† and 
§: details shown 
in table 1; 
‡ the prevalence of pre-DM was 16.3%(Dunstan, Zimmet et al. 2001). 
The cohort which progresses through the model includes pre-diabetics and 
undiagnosed diabetics without DR. 
 






|| Diet & exercise 
#
Lean 













=12 x 71% 
=8.5200% 
*Data based on the NSW Health Survey (2003) (NSW Health Department 2003); 
† Data based on the study by Tuomilehto, Lindstrom, et al., (2001) (Tuomilehto, 
Lindstrom et al. 2001).  
‡  the residual percentage; 
§ calculated by subtracting the 
achievement rate for both diet and exercise from that of diet; 
|| calculated by 
subtracting the achievement rate for both diet and exercise from that of exercise; 
# calculated by multiplying the achievement of diet by that of exercise. Numbers 
are rounded to four decimal places.   
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Table 4: The transition probabilities for non-sight threatening DR 
with intensive control and conventional blood glucose control  
 

























































PDR       #  0.0033 
(0.0220) 
The transition probabilities for non-sight threatening DR with intensive control 
and conventional blood glucose control represented in brackets. # represents the 
residual probability and numbers are rounded to four decimal places 
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Table 5: The transition probabilities to blindness from different 
stage of DR.  
 Intensive  control  Conventional control 
Pre-DR (no DR)  0.0171  0.0199 
MA only  0.0171  0.0199 
mild nPDR  0.0427  0.0497 
mod nPDR  0.0427  0.0497 
severe nPDR  0.0427  0.0497 
PDR 0.0544  0.0633 
ME 0.0783  0.0908 
Numbers are rounded to four decimal places. 
 
Table 6: Transitional probabilities to death by diabetes-related 
complications and other causes.  
 
 Intensive  control  Conventional control 
  DM related  Others  DM related  Others 
Pre-DR   0.0207  0.0148  0.0224  0.0146 
MA only  0.0207  0.0148  0.0224  0.0146 
mild nPDR  0.0207  0.0148  0.0224  0.0146 
mod nPDR  0.0284  0.0204  0.0309  0.0201 
severe nPDR  0.0320  0.0229  0.0347  0.0226 
PDR 0.0332  0.0238  0.0360  0.0235 
ME 0.0332  0.0238  0.0360  0.0235 
Blind 0.0332  0.0238  0.0360  0.0235 
Numbers are rounded to four decimal places. 
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Table 7: The Quality of Life Scores for different stages of Diabetic 
Retinopathy. 
 
 QoL  score 
Pre-DR (no DR)  0.8402 
MA only  0.8402 
mild nPDR  0.8360 
moderate nPDR  0.8182 




Numbers are rounded to four decimal places. 
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Table 8: Cost of Blindness  
Cost Type  Employed person  Unemployed 
CSTDA support * 
Employment $479.94   
Advocacy, info, & print 
disability 
$21.28 $21.28 
Admin $153.91  $153.91 
Centrelink Welfare support 
†
Disability Pension Payment  $10,847.20 - &12,922.20  $10,847.20 - &12,922.20 
Pharmaceutical Supplement  $75.40 - $150.80  $75.40 - $150.80 
Rent Assistance  $2,470.00 - $2615.60  $2,470.00 - $2615.60 




Travel Concessions  $1,470.56 - $21,840.00  $1,470.56 
Mobility Allowance  $1,856.40   
Others 
Occupational Therapy 
‡ $3,354.62 $3,354.62 
Work-related writing equip 
§ $1,583.00  
Total  $22,940.11 - $55,338.55  $19,050.77 - $21,416.77 
Weighted Average 
|| $20,226.57 - $31,593.30 
The average annual cost per user in each support category under the Commonwealth 
State/Territory Disability Agreement (CSTDA) in New South Wales (NSW) 
(Australian Institute of Health and Welfare 2004); 
† Centrelink welfare support for 
single and coupled residents (Department of Human Services 2005); 
‡ assume a visit 
to the therapist once a week at standard cost per visit (NSW Health Department 
2003); 
§ cost of equipment such as Braille, talking watches and so on (Vision 
Australia 2005); 
|| according to expert opinion, 70% of the blind are unemployed or 
underemployed. Note that the prices were inflated to 2005 levels, based on weighted 
average inflation rate (Australian Bureau of Statistics 2006). 
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Table 9: Univariate Sensitivity Analysis on health outcomes and 
costs.  
  LY SY QALY  Cost 
Prevalence 
Pre-DM   -8.33 (8.33) *  -8.44 (8.44) *  -8.38 (8.38) *  -4.04 (4.04) 
DM   -1.67 (1.67)  -1.56 (1.56)  -1.62 (1.62)  -4.19 (5.88) 








0.00 (0.00)  -0.00 (0.00)  0.00 (0.00)  0.86 (0.83) 




   -1.57  (1.63) 
Eye 
examination 
   0.45  (1.23) 
Laser 
Treatment 
   0.84  (0.85) 
Blindness     -7.15  (8.84)  * 
Total costs        -9.96 (10.02) * 
Table shows the percentage change in health outcomes or costs, with a 10% 
increase or decrease (in brackets) in parameters.  * indicates elasticity. 
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